Sonoma Pharmaceuticals
SNOA
17 hedge funds and large institutions have $574K invested in Sonoma Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.02% more ownership
Funds ownership: 0.28% → 0.3% (+0.02%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
6% less funds holding
Funds holding: 18 → 17 (-1)
21% less capital invested
Capital invested by funds: $726K → $574K (-$152K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$82.2K |
| 2 |
Renaissance Technologies
New York
|
+$49.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$23.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$153K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.69K |
| 4 |
Morgan Stanley
New York
|
-$64 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $221K | +$49.3K | +770 | +26% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $108K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $99K | +$20.6K | +321 | +23% |
|
|
4
Citadel Advisors
Miami,
Florida
| $76K | +$82.2K | +1,284 | New |
|
|
HFS
5
HBC Financial Services
Seattle,
Washington
| $34K | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $22K | +$23.6K | +369 | +18,450% |
|
7
BlackRock
New York
| $9K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $2K | -$9.8K | -153 | -82% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | -$2.69K | -42 | -62% |
|
10
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$153K | -1,906 | Closed |
|
|
12
Morgan Stanley
New York
| – | -$64 | -1 | -20% |
|
SNOA Hedge Fund Activity: Q2 2022 in Review
17 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2022, worth a combined $574K — down 21% from $726K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SNOA and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $82.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $153K sold.
- 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2022, down from 18 in Q1 2022.
- Funds reported $574K of Sonoma Pharmaceuticals stock for Q2 2022, down 21% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $82.2K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2022 was Two Sigma Securities, an estimated $153K sold.
Based on aggregated 13F filings for Q2 2022.